Recital 42, Directive (EU) 1998/44

In forcesince 6 Jul 1998cited 4×

Whereas, moreover, uses of human embryos for industrial or commercial purposes must also be excluded from patentability; whereas in any case such exclusion does not affect inventions for therapeutic or diagnostic purposes which are applied to the human embryo and are useful to it;

  • Judgment of the Court (Grand Chamber) of 18 October 2011. Oliver Brüstle v Greenpeace eV.Decision

    That interpretation is, in any event, identical to that adopted by the Enlarged Board of Appeal of the European Patent Office regarding Rule 28(c) of the Implementing Regulations to the CGEP, which uses precisely the same wording as …

    18 Oct 2011 · 62010CJ0034

  • Opinion of Mr Advocate General Bot delivered on 10 March 2011. Oliver Brüstle v Greenpeace eV.Decision

    Recital 42 in the preamble to the directive also states that ‘such exclusion does not affect inventions for therapeutic or diagnostic purposes which are applied to the human embryo and are useful to it’.

    10 Mar 2011 · 62010CC0034

  • Opinion of Advocate General Cruz Villalón delivered on 17 July 2014. International Stem Cell Corporation v Comptroller General of Patents, DDecision

    Recitals 5, 16, 20, 21, 36 to 39, and 42 of the Directive read as follows: … differences exist in the legal protection of biotechnological inventions offered by the laws and practices of the different Member States; … such differences …

    17 Jul 2014 · 62013CC0364

  • Judgment of the Court (Grand Chamber), 18 December 2014. International Stem Cell Corporation v Comptroller General of Patents, Designs and TDecision

    Recitals 1 to 3, 16, 37 to 39, 42 and 43 in the preamble to Directive 98/44 are worded as follows: ‘(1) Whereas biotechnology and genetic engineering are playing an increasingly important role in a broad range of industries and the …

    18 Dec 2014 · 62013CJ0364